Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Bromodomain-containing protein 4 is a protein encoded by the BRD4 gene. It plays a key role in transmission of epigenetic memory across cell divisions and transcription regulation. It promotes phosphorylation of Ser-2 of the C-terminal domain (CTD) of RNA polymerase II.
The Bromodomain-containing protein 4 – Drugs in Development research report provides a comprehensive overview on the therapeutics under development for Bromodomain-containing protein 4, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bromodomain-containing protein 4 and features dormant and discontinued projects.
Key Therapy Areas in the Bromodomain-containing protein 4 Pipeline Drugs Market
In the Bromodomain-containing protein 4 pipeline drugs market the key therapy areas are Oncology, Infectious Disease, Dermatology, Immunology, Cardiovascular, Genetic Disorders, Genito Urinary System and Sex Hormones, and Musculoskeletal Disorders.
Bromodomain-Containing Protein 4 Pipeline Drugs Market, by Therapy Areas
For more therapy arae insights, download a free report sample
Key MoA in the Bromodomain-Containing Protein 4 Pipeline Drugs Market
In the Bromodomain-Containing Protein 4 pipeline drugs market, the key MoA is Bromodomain Containing Protein 4 Inhibitor.
Bromodomain-Containing Protein 4 Pipeline Drugs Market Segmentation by RoA
The key routes of administration in the Bromodomain-Containing Protein 4 pipeline drugs market are oral, parenteral, inhalational, intratumor, intravenous, subcutaneous, and topical. Oral has the maximum number of pipeline products.
Bromodomain-Containing Protein 4 Pipeline Drugs Market Analysis, by RoA
To get more insights on key RoA, download a free sample report
Key Molecule Types in the BRD4 Pipeline Drugs Market
The key molecule types in the Bromodomain-Containing Protein 4 pipeline drugs market are Small Molecule, Antisense RNAi Oligonucleotide, and Gene-Modified Cell Therapy.
Bromodomain-Containing Protein 4 Pipeline Drugs Market, by Molecule Type
To get more insights on key molecule types, download a free sample report
Major Companies in the Bromodomain-Containing Protein 4 Pipeline Drugs Market
The major companies in the BRD4 pipeline drugs market are Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co, Bromodomain Pharmaceuticals Inc, C4 Therapeutics Inc, Checkpoint Therapeutics Inc, Chia Tai Tianqing Pharmaceutical Group Co Ltd, Constellation Pharmaceuticals Inc, AbbVie Inc, Amgen Inc and ConverGene LLC.
Bromodomain-Containing Protein 4 Pipeline Drugs Market, by Major Companies
For more company insights, download a free sample report
Bromodomain-Containing Protein 4 Pipeline Drugs Market Overview
Key Therapy Areas | Oncology, Infectious Disease, Dermatology, Immunology, Cardiovascular, Genetic Disorders, Genito Urinary System and Sex Hormones, and Musculoskeletal Disorders |
Key Mechanisms of action | Bromodomain Containing Protein 4 Inhibitor |
Key Routes of Administration | Oral, Parenteral, Inhalational, Intratumor, Intravenous, Subcutaneous, and Topical |
Key Molecule Types | Small Molecule, Antisense RNAi Oligonucleotide, and Gene-Modified Cell Therapy |
Major Companies | Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co, Bromodomain Pharmaceuticals Inc, C4 Therapeutics Inc, Checkpoint Therapeutics Inc, Chia Tai Tianqing Pharmaceutical Group Co Ltd, Constellation Pharmaceuticals Inc, AbbVie Inc, Amgen Inc and ConverGene LLC |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Bromodomain-Containing Protein 4
- The pipeline guide reviews pipeline therapeutics for Bromodomain-Containing Protein 4 by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Bromodomain-Containing Protein 4 therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Bromodomain-Containing Protein 4 therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Bromodomain-Containing Protein 4
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective countercstrategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Bromodomain-Containing Protein 4
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Bromodomain-Containing Protein 4 pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Amgen Inc
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Bromodomain Pharmaceuticals Inc
C4 Therapeutics Inc
Checkpoint Therapeutics Inc
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Constellation Pharmaceuticals Inc
ConverGene LLC
CSPC Pharmaceutical Group Ltd
Epigene Therapeutics Inc
Kainos Medicine Inc
Ningbo Wenda Pharmaceutical Technology Co Ltd
Nuvation Bio Inc
OHM Oncology
Phio Pharmaceuticals Corp
Plexium Inc
Plexxikon Inc
Ranok Therapeutics Co Ltd
Red Glead Discovery AB
Resverlogix Corp
Roivant Sciences Ltd
Shanghai Haihe Biopharma Co Ltd
Sierra Oncology Inc
SignalRx Pharmaceuticals Inc
VYNE Therapeutics Inc
Zenith Epigenetics Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key therapy areas in the Bromodomain-Containing Protein 4 pipeline drugs market?
In the Bromodomain-Containing Protein 4 pipeline drugs market the key therapy areas are Oncology, Infectious Disease, Dermatology, Immunology, Cardiovascular, Genetic Disorders, Genito Urinary System and Sex Hormones, and Musculoskeletal Disorders.
-
What are the key mechanisms of action in the Bromodomain-Containing Protein 4 pipeline drugs market?
In the Bromodomain-Containing Protein 4 pipeline drugs market, the key mechanism of action is Bromodomain Containing Protein 4 Inhibitor.
-
What are the key routes of administration in the Bromodomain-Containing Protein 4 pipeline drugs market?
The key routes of administration in the Bromodomain-Containing Protein 4 pipeline drugs market are oral, parenteral, inhalational, intratumor, intravenous, subcutaneous, and topical.
-
What are the key molecule types in the Bromodomain-Containing Protein 4 pipeline drugs market?
The key molecule types in the Bromodomain-Containing Protein 4 pipeline drugs market are Small Molecule, Antisense RNAi Oligonucleotide, and Gene-Modified Cell Therapy.
-
What are the major companies in the Bromodomain-Containing Protein 4 pipeline drugs market?
In the Bromodomain-Containing Protein 4 pipeline drugs market the major companies are Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co, Bromodomain Pharmaceuticals Inc, C4 Therapeutics Inc, Checkpoint Therapeutics Inc, Chia Tai Tianqing Pharmaceutical Group Co Ltd, Constellation Pharmaceuticals Inc, AbbVie Inc, Amgen Inc and ConverGene LLC.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.